amyotrophic lateral sclerosis

Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

a·my·o·tro·phic lateral sclerosis

 (ā′mī-ə-trō′fĭk, -trŏf′ĭk, ā-mī′-)
n. Abbr. ALS
A chronic, progressive disease marked by gradual degeneration of the nerve cells in the spinal cord that control voluntary muscle movement, causing muscle weakness, atrophy, and eventual paralysis. Also called Lou Gehrig's disease.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

amyotrophic lateral sclerosis

(Pathology) a form of motor neurone disease in which degeneration of motor tracts in the spinal cord causes progressive muscular paralysis starting in the limbs. Also called: Lou Gehrig's disease
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

a•my•o•troph′ic lat′eral sclero′sis

(ˌeɪ maɪ əˈtrɒf ɪk, -ˈtroʊ fɪk, eɪˌmaɪ ə-)
a nervous system disease in which degeneration of motor neurons in the brain stem and spinal cord leads to atrophy and paralysis of the voluntary muscles. Abbr.: ALS Also called Lou Gehrig's disease.
[1885–90; a-6 + myo- + -trophic]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyotrophic lateral sclerosis - thickening of tissue in the motor tracts of the lateral columns and anterior horns of the spinal cordamyotrophic lateral sclerosis - thickening of tissue in the motor tracts of the lateral columns and anterior horns of the spinal cord; results in progressive muscle atrophy that starts in the limbs
nervous disorder, neurological disease, neurological disorder - a disorder of the nervous system
induration, sclerosis - any pathological hardening or thickening of tissue
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
announced today that it has received orphan drug designation for NPT520-34 for the treatment of amyotrophic lateral sclerosis or ALS.
Specifically, the acquisition of Nightstar Therapeutics has provided us with two potentially first-in-class mid- to late-stage gene therapy programs in specialty ophthalmology, and we initiated two new studies in our priority areas of multiple sclerosis and amyotrophic lateral sclerosis. We continued to allocate capital, and we remain focused on investing in the areas we believe have the highest potential return for shareholders," said Biogen CEO Michel Vounatsos.
Pharmaceutical company Aquestive Therapeutics Inc (NASDAQ:AQST) said on Tuesday that it has successfully filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for the investigational product riluzole oral film (ROF) for the treatment of amyotrophic lateral sclerosis (ALS).
The allowed claims cover the isolated cells as well as their use in the manufacture of a drug for treating a CNS disease or disorder, selected from the group consisting of: Parkinson's, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease and Huntingdon's disease.
Background: Ongoing efforts have been made to identify new neuroimaging markers to track amyotrophic lateral sclerosis (ALS) progression.
A Keio University research team will begin clinical tests for the treatment of amyotrophic lateral sclerosis (ALS), administering ALS patients an existing drug used for another disease, which is confirmed to be effective in experiments with induced pluripotent stem (iPS) cells.
[ClickPress, Thu Sep 27 2018] Amyotrophic Lateral Sclerosis (ALS) is a neurological disease that affects nerve cells in the brain and spinal cords which controls the activity of voluntary muscles.
CytRx's milestone payment follows the dosing of the first patient under the Phase 3 clinical trial evaluating arimoclomol in patients with amyotrophic lateral sclerosis (ALS).
GERMANTOWN, Md., May 3, 2018 -- Comparison of data from combined cohorts in Phase 1 and 2 clinical trials versus historical controls validates plans for additional trials to evaluate benefits of using neural stem cells to treat amyotrophic lateral sclerosis, or ALS, Neuralstem said.
He was, simultaneously, a source of inspiration for both scientists and patients of amyotrophic lateral sclerosis (ALS).

Full browser ?